Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function

被引：0
|
作者：
J. F. W. Hoogkamer
C. H. Kleinbloesem
M. Ouwerkerk
A. Högemann
A. Nokhodian
W. Kirch
E. Weidekamm
机构：
[1] Clin-Pharma Research,
[2] CH-4127 Birsfelden,undefined
[3] Switzerland Tel.: +41-61-313 3220; Fax: +41-61-313 3242,undefined
[4] Takeda Euro Research and Development Centre,undefined
[5] Frankfurt am Main,undefined
[6] Germany,undefined
[7] Medizinische Fakultät Technische Universität Dresden,undefined
[8] Dresden,undefined
[9] Germany,undefined
来源：
European Journal of Clinical Pharmacology | 1998年 / 54卷
关键词：
Key words Candesartan; Hepatic impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: The influence of liver disease on the pharmacokinetics of candesartan, a long-acting selective AT1 subtype angiotensin II receptor antagonist was studied.
引用
收藏
页码：341 / 345
页数：4
相关论文
共 50 条
  • [1] Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function
    Hoogkamer, JFW
    Kleinbloesem, CH
    Ouwerkerk, M
    Högemann, A
    Nokhodian, A
    Kirch, W
    Weidekamm, E
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (04) : 341 - 345
  • [2] Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function
    Buter, H
    Navis, GY
    Woittiez, AJJ
    de Zeeuw, D
    de Jong, PE
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 54 (12) : 953 - 958
  • [3] Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function
    H. Buter
    G. Y. Navis
    A. J. J. Woittiez
    D. de Zeeuw
    P. E. de Jong
    European Journal of Clinical Pharmacology, 1999, 54 : 953 - 958
  • [4] Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function
    Miyazawa, Y
    Blum, RA
    Schentag, JJ
    Kamimura, H
    Matsushima, H
    Swarz, H
    Ito, Y
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (09): : 603 - 621
  • [5] Pharmacokinetics and safety of gadobenate dimeglumine (Multihance) in subjects with impaired liver function
    Davies, BE
    Kirchin, MA
    Bensel, K
    Lorusso, V
    Davies, A
    Parker, JR
    Lafrance, ND
    INVESTIGATIVE RADIOLOGY, 2002, 37 (05) : 299 - 308
  • [6] Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function
    Tao, Jun
    Liu, Shuaibing
    Zhao, Ying Ying
    Qi, Lei
    Yan, Pangke
    Wu, Nan
    Liu, Xiao
    Liu, Dongwei
    Tian, Xin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [7] The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function
    Everson, G
    Lasseter, KC
    Anderson, KE
    Bauer, LA
    Carithens, RL
    Wilner, KD
    Johnson, A
    Anziano, RJ
    Smolarek, TA
    Turncliff, RZ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 : 21S - 26S
  • [8] The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function
    Aweeka, F
    Jayesekara, D
    Horton, M
    Swan, S
    Lambrecht, L
    Wilner, KD
    Sherwood, J
    Anziano, RJ
    Smolarek, TA
    Turncliff, RZ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 : 27S - 33S
  • [9] Pharmacokinetics of nilotinib in subjects with normal or impaired hepatic function
    Holland, Jaymes
    Tanaka, Chiaki
    Zhou, Wei
    Sethuraman, Venkat
    Heuman, Douglas M.
    Schran, Horst
    BLOOD, 2007, 110 (11) : 702A - 702A
  • [10] Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function
    Phillips, Marc
    Smith, William
    Balan, Guhan
    Ward, Suzanne
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (03): : 279 - 284
12345